Ampullary Adenocarcinoma...Good PS….Targeted Systemic Therapies:...Useful in Certain Circumstances:...Entrectinib (if NTRK gene fusion positive).
Sensitive: C1 - Off-label
(Approved for Solid Tumor)
entrectinib (Rozlytrek ®) is accepted for use within NHSScotland.
entrectinib (Rozlytrek) is accepted for use within NHSScotland....as monotherapy for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion